Annual Meeting of the NCI Cohort Consortium (Abstract Submission): Submission #12

Submission information
Submission Number: 12
Submission ID: 127577
Submission UUID: 7f5d9978-95b5-4d53-8853-a6249d46acac

Created: Fri, 09/13/2024 - 14:24
Completed: Fri, 09/13/2024 - 16:02
Changed: Fri, 09/13/2024 - 16:02

Remote IP address: 10.208.28.69
Submitted by: Anonymous
Language: English

Is draft: No
Presenter's First Name: Benjamin
Presenter's Last Name: Cairns
Title (eg: professor, assistant professor, chair, etc): Dr
Degree(s) Ph.D.
Contact Email: Ben.Cairns@ourfuturehealth.org.uk
Organization: Our Future Health
Project Title: Our Future Health: A New Prospective Cohort for Translational Research
Additional Authors
  1. First Name: Michael
    Middle Initial: B
    Last Name: Cook
    Degree(s): Ph.D.
    Organization: Our Future Health
  2. First Name: David
    Middle Initial: J
    Last Name: Hunter
    Degree(s): M.B.B.S. MPH Sc.D.
    Organization: University of Oxford; Our Future Health
  3. First Name: Raghib
    Last Name: Ali
    Degree(s): M.D. MPH
    Organization: Our Future Health
Abstract: Background: Our Future Health is a new UK-wide prospective cohort study supported by the UK Government, industry and charity sectors. Our objective is to recruit 5 million adult residents of the UK to facilitate aetiologic and translational health research, aiming to discover and test more effective approaches to prevention, earlier detection and treatment of diseases.

Methods: The sampling frame for Our Future Health is the total UK adult population. Through invitations and open enrolment, we aim to recruit a cohort that reflects the diversity of the UK population in terms of age, ethnicity, socioeconomic status and geography. Participants complete a questionnaire and attend an appointment for physical measurements and blood sampling, and are genotyped using a custom array with a genome-wide backbone for imputation and extensive coverage of disease- and phenotype-associated variants. Priority data linkages include primary and secondary care records, and cancer and death registrations, in each of the four UK nations.

Results: To date, 1.8 million participants have consented to join Our Future Health, of which 1.3 million have completed the broad baseline questionnaire and over 1 million have donated blood for genotyping and biobanking of plasma, buffy coat and DNA.

Discussion: Key translational aspects of the study include the forthcoming ability for study proposals to request access to baseline blood samples, and for investigator-led recontact studies to recruit participants based on demographics, phenotypes, genotypes or disease risk for risk-stratified research. Our Future Health (ourfuturehealth.org.uk) is already open for data access study proposals.